Genetics-guided therapy in neuroendocrine carcinoma: response to BRAF- and MEK-inhibitors

CONCLUSIONS: BRAF-mutated NEC is sensitive to treatment with BRAF- and MEK-inhibitor combination. These results further support that DNA sequencing should be considered as standard of care in NECs to screen for potential treatment targets.PMID:38716076 | PMC:PMC11075439 | DOI:10.48101/ujms.v129.10660

Source: Upsala Journal of Medical Sciences - May 8, 2024 Category: General Medicine Authors: Lovisa Falkman Anders Sundin Britt Skogseid Johan Botling Yvette Bernardo G öran Wallin Liang Zhang Staffan Welin Ieva Lase Kazhan Mollazadegan Joakim Crona Source Type: research